SCHEMBL2936866

SCHEMBL2936866

O=C1CN(Cc2ccncc2C2CCCCC2)C(=O)N1c1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.39
CTSS P25774 1/20 0.36
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
TEAD1 P28347 1/20 0.33
CYP17A1 P05093 5/20 0.32
SLC6A9 P48067 1/20 0.32
TAS2R8 Q9NYW2 2/20 0.32
HRH4 Q9H3N8 1/20 0.32
ENPP2 Q13822 1/20 0.31
CACNA1B Q00975 1/20 0.31
PTGS1 P23219 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934706 0.85 PTGS1 (0.46) IGF1RCTSSLMNAMAPK1HTT
SCHEMBL2936095 0.84 GCGR (0.35) CYP17A1TAS2R8PPARDPPARA
SCHEMBL2931697 0.84 IGF1R (0.40) IGF1RCYP17A1TAS2R8ENPP2
SCHEMBL2940350 0.84 IGF1R (0.41) IGF1RCTSSLMNAMAPK1HTT
SCHEMBL2935784 0.84 IGF1R (0.41) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL2942410 0.83 IGF1R (0.42) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL2938324 0.83 IGF1R (0.42) IGF1RCTSSLMNAMAPK1HTT
SCHEMBL2937993 0.83 IGF1R (0.40) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL2934894 0.83 IGF1R (0.40) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL2932862 0.83 IGF1R (0.40) IGF1RLMNAMAPK1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885CTSS 2419/4885LMNA 1988/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885CTSS 2702/4885LMNA 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.